Silo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide Patent
Silo Pharma (OTCQB:SILO) announced a significant development in its product pipeline, receiving a notice of allowance for a patent from the United States Patent Office pertaining to its Central Nervous System Homing Peptide. This novel peptide aims to enhance the delivery of psychedelics, including Psilocybin, for therapeutic applications. CEO Eric Weisblum expressed optimism about expanding their intellectual property portfolio to cover markets for potential therapeutic applications, addressing conditions like depression and PTSD.
- Patent allowance for Central Nervous System Homing Peptide enhances potential therapeutic applications.
- Expansion of intellectual property portfolio can lead to new market opportunities.
- None.
Central Nervous System Homing Peptide under development to deliver Psychedelics including Psilocybin
Englewood Cliffs NJ, July 27, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB:SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announcedthat the United States Patent Office has issued a notice of allowance for a patent application related to the Company's Central Nervous System Homing Peptide.
"We are pleased to have been granted this patent by the United States Patent and Trademark Office for our novel homing peptide," said Eric Weisblum, CEO of Silo Pharma. "We will continue to expand our intellectual property portfolio related to markets where our novel therapeutics can be applied.”
About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry. For more information, visit www.silopharma.com
Safe Harbor and Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.
Investor Relations Contact:
Hayden IR
Brett Maas
646-536-7331
Email: brett@haydenir.com
FAQ
What recent patent was granted to Silo Pharma?
What are the potential applications of Silo Pharma's new peptide?
What is the significance of the patent for Silo Pharma's future?
When was the patent notice issued to Silo Pharma?
